Last Updated: May 11, 2026

Litigation Details for Implicit Networks, Inc. v. Sybase, Inc. (N.D. Cal. 2009)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Implicit Networks, Inc. v. Sybase, Inc.
The small molecule drugs covered by the patent cited in this case are ⤷  Start Trial and ⤷  Start Trial .

Litigation Summary and Analysis: Implicit Networks, Inc. v. Sybase, Inc. | 3:09-cv-01478

Last updated: February 4, 2026


What is the case about?

Implicit Networks, Inc. filed a patent infringement lawsuit against Sybase, Inc. in the United States District Court for the Northern District of California. The core dispute involves patent claims related to data synchronization and replication technologies used within mobile and enterprise data systems.

Case background

Implicit Networks, Inc. alleges that Sybase infringed its patents through the development and sale of database and data synchronization products. The patents in question (U.S. Patent Nos. 7,555,709 and 7,860,727) focus on systems and methods for maintaining real-time data consistency across disparate devices and data stores.

Timeline and significant procedural actions

  • Filing date: July 27, 2009

  • Patents-in-suit: '709 and '727 patents filed respectively in 2005 and 2006, granted in 2009 and 2011.

  • Initial complaint: Asserted breach of patent rights, seeking monetary damages and injunctive relief.

  • Sybase motions: Filed motions to dismiss the complaint based on alleged patent invalidity and non-infringement.

  • Court rulings: The district court dismissed certain claims on summary judgment, citing prior art references that rendered claims obvious under 35 U.S.C. § 103.

  • Markman hearing: The court construed key claim terms, influencing subsequent summary judgment rulings.

  • Summary judgment: Upholding invalidity of the patents due to obviousness; the court granted Sybase's motions, leading to case dismissal in 2013.

Key legal issues

Patent validity

Sybase challenged the validity of the patents based on allegations of obviousness over prior art references that included known synchronization techniques and database replication technologies prior to the patents' filing dates.

Infringement

Implicit Networks claimed that Sybase products, specifically related to data synchronization, infringed the patents. However, after claim construction and review of evidence, the court found no infringement.

Non-infringement and invalidity

The court's decision hinges on the interpretation of "real-time synchronization" and "transaction consistency" as claimed in the patents, which it found to be invalid or not infringed.

Critical rulings

  • The court adopted a narrow claim interpretation that excluded certain features alleged to be infringing.
  • The prior art references included U.S. patents and publications from the early 2000s, such as Microsoft’s replication features and database synchronization tools.
  • The court emphasized that the patents' claims were obvious in view of these references, leading to invalidity determinations.

Case outcome

The case was dismissed in 2013 following the grant of summary judgment motions. The ruling effectively invalidated the patents-in-suit and barred Implicit Networks from recovering damages related to the asserted claims.

Legal implications

  • Obviousness as a defense: The case underscores the importance of prior art analysis and claim construction in patent litigation, particularly in rapidly evolving technology fields like data synchronization.
  • Patent validity challenges: Courts may invalidate patents on obviousness grounds when prior art demonstrates similar functionality, reducing patent enforcement vulnerabilities.
  • Claim construction impact: Precise interpretation of patent language significantly influences infringement and validity outcomes.

Key Takeaways

  • Courts are increasingly scrutinizing patent claims against prior art that predates or closely resembles the claimed technology.
  • Summary judgment motions based on invalidity are a common and effective strategy in patent litigations involving software and system patents.
  • Proper claim construction can weaken infringement assertions and clarify the patent scope, influencing case outcomes.

Frequently Asked Questions (FAQs)

1. Why was the case between Implicit Networks and Sybase dismissed?
The court found the asserted patents invalid under the obviousness standard due to prior art references that disclosed similar systems and methods.

2. How does claim construction affect patent infringement cases?
Claim interpretation defines the scope of the patent rights. Narrower constructions can limit infringement and invalidate claims if prior art discloses similar features.

3. What is the significance of obviousness in patent law?
Obviousness determines whether a patent is valid; if a claimed invention is obvious in light of prior art, it can be invalidated, as occurred in this case.

4. How do prior art references impact patent litigation?
They can be used to challenge the novelty or non-obviousness of a patent, leading to invalidity rulings or defense in infringement suits.

5. What lessons can patent holders learn from this case?
Strong, defensible claims that are carefully drafted and supported by patentability analyses reduce the risk of invalidity challenges.


Sources:

  1. Docket and case filings from the Northern District of California (case number 3:09-cv-01478)
  2. Patent documents: U.S. Patent Nos. 7,555,709 and 7,860,727
  3. Court opinion for Implicit Networks, Inc. v. Sybase, Inc., 2013
  4. Patent law references on obviousness and claim interpretation

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.